Bristol Erbitux Ultimatum: Company Wants Control Of FDA Negotiations
Bristol-Myers Squibb wants responsibility for the regulatory and clinical future of Erbitux under a proposed restructuring of the company's relationship with ImClone
Bristol-Myers Squibb wants responsibility for the regulatory and clinical future of Erbitux under a proposed restructuring of the company's relationship with ImClone